<DOC>
	<DOCNO>NCT01093508</DOCNO>
	<brief_summary>The APD916-001 study design primarily evaluate safety tolerability APD916 administer single dose</brief_summary>
	<brief_title>Single-dose Safety Study APD916 Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , single-dose escalation study 9 dose cohort ( 1 , 2 , 5 , 10 , 20 , 30 , 45 , 70 90 mg ) comprise 8 subject ( 2 receive placebo , 6 receive APD916 ) . Each cohort assign receive single dose APD916 . After dose within first cohort complete safety data review identifies tolerability issue , principal investigator ( PI ) Sponsor agree safe proceed , subject next cohort may dose .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<criteria>Healthy male female age 1845 year Body weight 50100 kg ( 110220 pound ) Eligible female subject nonpregnant , evidence negative serum pregnancy test Screening urine dipstick pregnancy test Day 1 ( CheckIn ) ; nonlactating ; surgically sterile , postmenopausal , agree continue use medically accept method birth control least 1 month last study medication administration . Eligible male subject either surgically sterile ( i.e. , vasectomy ) , least 3 month prior screen , agree use condom spermicide sexually active female partner use acceptable method birth control study 1 month . Exclusion Criteria Subject donate blood , significant blood loss within 56 day dose History smoke tobacco use within 3 month prior dose History epilepsy seizure disorder Recent history ( within 2 year prior screen visit ) sleep disorder History ( within 2 year prior screen visit ) ADD ADHD Traveled across 3 time zone within 2 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>